ARTICLE | Finance
Back to the bone
Why OrbiMed's Stephen Squinto is buying back into bone biology
October 5, 2015 7:00 AM UTC
In one of his first investments since joining OrbiMed Advisors in January, Stephen Squinto is returning to a space he knows well - biologics for an Orphan bone disease. The result was OrbiMed leading last week's $35 million series A round for Therachon.
New Enterprise Associates also participated and joined seed investors Inserm Transfert Initiative and Versant Ventures. ...